A 3-year review of new psychoactive substances in casework

Forensic Science International

Volumn 243, Issue , 2014, Pages 55-60

  Elliott, Simon ^a   Evans, Julie ^a  

^a Inverness Medical Innovations   (United States)

Author keywords

Cathinones; Designer drugs; Fatalities; New psychoactive substances

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 FLUOROMETHCATHINONE; 4 METHYLAMPHETAMINE; 4 METHYLETHCATHINONE; 4' METHYLMETHCATHINONE; ALPHA METHYLTRYPTAMINE; BUTYLONE; CANNABINOID DERIVATIVE; COCAINE; DESOXYPIPRADROL; HYDROXYZINE; KETAMINE; METHOXETAMINE; METHYLONE; NAPHYRONE; PENTEDRONE; PENTYLONE; PHENETHYLAMINE; PHENYTOIN; PIPERAZINE DERIVATIVE; PSYCHOTROPIC AGENT; QUININE; RECREATIONAL DRUG; TRYPTAMINE; UNCLASSIFIED DRUG; 1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; CANNABINOID; CATHINONE; DESIGNER DRUG; DRUG; NARCOTIC AGENT;

ACCIDENTAL DEATH; ADULT; ARTICLE; AUTOPSY; BLOOD LEVEL; BLOOD SAMPLING; CASE STUDY; CAUSE OF DEATH; CLINICAL ARTICLE; CRIMINAL BEHAVIOR; DRUG ABUSE; DRUG FATALITY; DRUG MISUSE; FEMALE; FORENSIC IDENTIFICATION; FORENSIC TOXICOLOGY; HUMAN; MALE; PRIORITY JOURNAL; SUICIDE; URINE LEVEL; ANALYTIC METHOD; BLOOD; CONCENTRATION (PARAMETERS); DRUG OVERDOSE; URINE; ADDICTION; MORTALITY;

CAUSE OF DEATH; DESIGNER DRUGS; FORENSIC TOXICOLOGY; HUMANS; NARCOTICS; PHARMACEUTICAL PREPARATIONS; PSYCHOTROPIC DRUGS; SUBSTANCE-RELATED DISORDERS; SUICIDE;

EID: 84899880097     PISSN: 03790738     EISSN: 18726283     Source Type: Journal    
DOI: 10.1016/j.forsciint.2014.04.017     Document Type: Article

References (26)

1. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Annual Report on the State of the Drugs Problem in Europe 2012, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Available at 〈http://www.emcdda.europa.eu/publications/annual-report/2012〉 (accessed March 2014).
2. Collins M. Some new psychoactive substances: precursor chemicals and synthesis-driven end-products. Drug Test. Anal. 2011, 3:404-416.
3. Sumnall H.R., Evans-Brown M., McVeigh J. Social, policy, and public health perspectives on new psychoactive substances. Drug Test. Anal. 2011, 3:515-523.
4. Favretto D., Pascali J.P., Tagliaro F. New challenges and innovation in forensic toxicology: focus on the New Psychoactive Substances. J. Chromatogr. A. 2013, 1287:84-95.
5. Elliott S. Cat and mouse: the analytical toxicology of designer drugs. Bioanalysis 2011, 3:249-251.
6. Archer R.P., Treble R., Williams K. Reference materials for new psychoactive substances. Drug Test. Anal. 2011, 3:505-514.
7. Elliott S.P., Brandt S.D., Freeman S., Archer R.P. A.M.T. (3-(2-aminopropyl)indole) and 5-IT (5-(2-aminopropyl)indole): an analytical challenge and implications for forensic analysis. Drug Test. Anal. 2013, 5:196-202.
8. Soh Y.N.A., Elliott S. An investigation of the stability of emerging new psychoactive substances. Drug Test. Anal. 2013, 10.1002/dta.1576.
9. Durkin E., Elliott S., Evans J. The High Prevalence of Cathinone-derivatives in Suicides-A Comparative Study 2010, Society of Forensic Toxicologists Meeting, Richmond, VA, (poster).
10. Wijlaars L.P., Nazareth I., Whitaker H.J., Evans S.J., Petersen I. Suicide-related events in young people following prescription of SSRIs and other antidepressants: a self-controlled case series analysis. BMJ Open 2013, 3(9):e003247. 10.1136/bmjopen-2013-003247.
11. Gunnell D., Saperia J., Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ 2005, 330:385. (erratum in: BMJ. 333 2006 30).
12. Gibbons S. 'Legal highs'-novel and emerging psychoactive drugs: a chemical overview for the toxicologist. Clin. Toxicol. (Phila.) 2012, 50:15-24.
13. Yarema M.C., Becker C.E. Key concepts in postmortem drug redistribution. Clin. Toxicol (Phila.) 2005, 43:235-241.
14. Han E., Kim E., Hong H., Jeong S., Kim J., In S., Chung H., Lee S. Evaluation of postmortem redistribution phenomena for commonly encountered drugs. Forensic Sci. Int. 2012, 219:265-271.
15. Cosbey S.H., Peters K.L., Quinn A., Bentley A. Mephedrone (methylmethcathinone) in toxicology casework: a Northern Ireland perspective. J. Anal. Toxicol. 2013, 37:74-82.
16. Maskell P.D., De Paoli G., Seneviratne C., Pounder D.J. J. Anal. Toxicol. 2011, 35:188-191.
17. Johnson R.D., Botch-Jones S.R. The stability of four designer drugs: MDPV, mephedrone, BZP and TFMPP in three biological matrices under various storage conditions. J. Anal. Toxicol. 2013, 37:51-55.
18. Sørensen L.K. Determination of cathinones and related ephedrines in forensic whole-blood samples by liquid-chromatography-electrospray tandem mass spectrometry. J. Chromatogr. B 2011, 879:727-736.
19. Miotto K., Striebel J., Cho A.K., Wang C. Clinical pharmacological aspects of bath salt use: a review of the literature and case reports. Drug Alcohol Depend. 2013, 132:1-12.
20. Prosser J.M., Nelson L.S. The toxicology of bath salts: a review of synthetic cathinones. J. Med. Toxicol. 2012, 8:33-42.
21. Hill S.L., Thomas S.H. Clinical toxicology of newer recreational drugs. Clin. Toxicol. 2011, 49:705-719.
22. Bosak A., LoVecchio F., Levine M. Recurrent seizures and serotonin syndrome following 2C-I ingestion. J. Med. Toxicol. 2013, 9:196-198.
23. Mugele J., Nañagas K.A., Tormoehlen L.M. Serotonin syndrome associated with MDPV use: a case report. Ann. Emerg. Med. 2012, 60:100-102.
24. Warrick B.J., Wilson J., Hedge M., Freeman S., Leonard K., Aaron C. Lethal serotonin syndrome after methylone and butylone ingestion. J. Med. Toxicol. 2012, 8:65-68.
25. Corkery J.M., Elliott S., Schifano F., Corazza O., Ghodse A.H. M.D.A.I. (5,6-methylenedioxy-2-aminoindane 6,7-dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine 'sparkle'; 'mindy') toxicity: a brief overview and update. Hum. Psychopharmcol. 2013, 28:345.
26. Corkery J.M., Elliott S., Schifano F., Corazza O., Ghodse A.H. 2-DPMP (desoxypipradrol, 2-benzhydrylpiperidine, 2-phenylmethylpiperidine) and D2PM (diphenyl-2-pyrrolidin-2-yl-methanol, diphenylprolinol): a preliminary review. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 39:253-258.